Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change

Sundeep Ganoria

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.

PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change

Zacks Equity Research

Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNANegative Net Change